Journal
ISCIENCE
Volume 26, Issue 11, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2023.108180
Keywords
-
Categories
Ask authors/readers for more resources
Mutation targeted therapy in cystic fibrosis is not suitable for all patients, especially those with rare variants. Our study analyzed the effects of these variants on protein stability and performed functional characterization using different cell models. We found that treatment with CFTR modulators could improve CFTR function and increase CFTR protein levels. In vivo experiments also showed positive effects of VX770 treatment on CF symptoms.
Mutation targeted therapy in cystic fibrosis (CF) is still not eligible for all CF subjects, especially for cases carrying rare variants such as the CFTR genotype W57G/A234D (c.169T>G/c.701C>A). We performed in silico analysis of the effects of these variants on protein stability, which we functionally characterized using colonoids and reprogrammed nasal epithelial cells. The effect of mutations on cystic fibrosis trans membrane conductance regulator (CFTR) protein was analyzed by western blotting, forskolin-induced swelling (FIS), and Ussing chamber analysis. We detected a residual CFTR function that increases following treatment with the CFTR modulators VX661 +/- VX445 +/- VX770, correlates among models, and is associated with increased CFTR protein levels following treatment with CFTR correctors. In vivo treatment with VX770 reduced sweat chloride concentration to non-CF levels, increased the number of CFTR-dependent sweat droplets, and induced a 6% absolute increase in predicted FEV1% after 27 weeks of treatment indicating the relevance of theratyping with patient-derived cells in CF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available